Is China A Black Swan For Big Pharma? (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
[Editor's note: This is part two of a two part story; part one appeared in PharmAsia News, April 25, 2010.]
You may also be interested in...
GSK Carving Out Strategic Strengths In Emerging Markets: Euro-Biotech Partnering Summit
GSK VP Paul Bolno on market-specific opportunities in Asia.
Ascletis Gets Record Funding From China’s Hangzhou Development Zone For HIV/AIDs Drug Research
Hangzhou National Hi-Tech Industrial Development Zone awarded U.S.-China hybrid Ascletis a $1.6 million grant to fund research for HIV/AIDs drugs, the highest amount paid to date by a program aimed at wooing top Chinese national research talent back home.
PharmAsia News Favorite Stories From 2011
If you missed some of the highlights of 2011, here’s your opportunity to check out some of our favorite stories from the year, as chosen by the editors of PharmAsia News.